The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study
Open accessAbstract
Background— Oral estrogen therapy increases the risk of venous thromboembolism (VTE) in postmenopausal women. Transdermal estrogen may be safer. However, currently available data have limited the ability to investigate the wide variety of types of progestogen. Methods and Results— We performed a multicenter case–control study of VTE among postmenopausal women 45 to 70 years of age between 1999 and 2005 in France. We recruited 271 consecutive cases with a first documented episode of idiopathic VTE (208 hospital cases, 63 outpatient cases) and 610 controls (426 hospital controls, 184 community controls) matched for center, age, and admission date. After adjustment for potential confounding factors, odds ratios (ORs) for VTE in current users of oral and transdermal estrogen compared with nonusers were 4.2 (95% CI, 1.5 to 11.6) and 0.9 (95% CI, 0.4 to 2.1), respectively. There was no significant association of VTE with micronized progesterone and pregnane derivatives (OR, 0.7; 95% CI, 0.3 to 1.9 and OR, 0.9; 95% CI, 0.4 to 2.3, respectively). In contrast, norpregnane derivatives were associated with a 4-fold-increased VTE risk (OR, 3.9; 95% CI, 1.5 to 10.0). Conclusions— Oral but not transdermal estrogen is associated with an increased VTE risk. In addition, our data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect to thrombotic risk. If confirmed, these findings could benefit women in the management of their menopausal symptoms with respect to the VTE risk associated with oral estrogen and use of progestogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Pharmacology of estrogens and progestogens: influence of different routes of administration
Kuhl, H. (2005) · Climacteric · doi:10.1080/13697130500148875 · Cited by 835
Risk of venous thromboembolism in users of hormone replacement therapy
Daly, E., Vessey, M. P., Hawkins, M. M., Carson, J. L., Gough, P., & Marsh, S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07113-9 · Cited by 819
Scarabin, P.-Y., Oger, E., & Plu-Bureau, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14066-4 · Cited by 714
Self-citationEstrogen plus progestin and risk of venous thrombosis
Cushman, M. (2004) · JAMA · doi:10.1001/jama.292.13.1573 · Cited by 632
Jick, H., Derby, L. E., Myers, M. W., Vasilakis, C., & Newton, K. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07114-0 · Cited by 602
Prospective study of exogenous hormones and risk of pulmonary embolism in women
Grodstein, F., Stampfer, M. J., Goldhaber, S. Z., Manson, J. E., Colditz, G. A., Speizer, F. E., Willett, W. C., & Hennekens, C. H. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07308-4 · Cited by 571
Canonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569
Self-citationKEEPS: The Kronos Early Estrogen Prevention Study
Harman, S., Brinton, E., Cedars, M., Lobo, R., Manson, J., Merriam, G., Miller, V., Naftolin, F., & Santoro, N. (2005) · Climacteric · doi:10.1080/13697130500042417 · Cited by 397
Scarabin, P.-Y., Alhenc-Gelas, M., Plu-Bureau, G., Taisne, P., Agher, R., & Aiach, M. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.3071 · Cited by 348
Self-citationHormone replacement therapy and risk of venous thromboembolism: population based case-control study
Gutthann, S. P., Rodriguez, L. A. G., Castellsague, J., & Oliart, A. D. (1997) · BMJ · doi:10.1136/bmj.314.7083.796 · Cited by 338
Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results
Haas, J. S., Kaplan, C. P., Gerstenberger, E. P., & Kerlikowske, K. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-3-200402030-00009 · Cited by 314
Høibraaten, E., Qvigstad, E., Arnesen, H., Larsen, S. U., Wickström, E., & Sandset, P. (2000) · PubMed · Cited by 266
Prentice, R. L., Langer, R., Stefanick, M. L., Howard, B. V., Pettinger, M., Anderson, G., Barad, D., Curb, J. D., Kotchen, J., Kuller, L., et al. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi223 · Cited by 264
Vickers, M. R., MacLennan, A. H., Lawton, B., Ford, D., Martin, J., Meredith, S. K., DeStavola, B. L., Rose, S., Dowell, A., Wilkes, H. C., et al. (2007) · BMJ · doi:10.1136/bmj.39266.425069.ad · Cited by 254
Straczek, C., Oger, E., Yon de Jonage-Canonico, M. B., Plu-Bureau, G., Conard, J., Meyer, G., Alhenc-Gelas, M., Lévesque, H., Trillot, N., Barrellier, M.-T., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.565556 · Cited by 200
Self-citationRisk of idiopathic venous thromboembolism in users of progestagens alone
Vasilakis, C., Jick, H., & del Mar Melero-Montes, M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04394-9 · Cited by 189
Nestorone®: a progestin with a unique pharmacological profile
Kumar, N. (2000) · Steroids · doi:10.1016/s0039-128x(00)00119-7 · Cited by 184
Esterified Estrogens and Conjugated Equine Estrogens and the Risk of Venous Thrombosis
Smith, N. L. (2004) · JAMA · doi:10.1001/jama.292.13.1581 · Cited by 174
Oger, E., Alhenc-Gelas, M., Lacut, K., Blouch, M.-T., Roudaut, N., Kerlan, V., Collet, M., Abgrall, J.-F., Aiach, M., Scarabin, P.-Y., et al. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000087141.05044.1f · Cited by 167
Self-citationRisk of venous thromboembolism with cyproterone or levonorgestrel contraceptives
Vasilakis-Scaramozza, C., & Jick, H. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06522-9 · Cited by 160
Varas‐Lorenzo, C., guez, L. A. G. A. R., Cattaruzzi, C., Troncon, M. G., Agostinis, L., & Perez‐Gutthann, S. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009461 · Cited by 145
Post, M. S., Thomassen, S., Thomassen, S., van der Mooren, M. J., van Baal, W. M., Rosing, J., Kenemans, P., & Stehouwer, C. D. A. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000074146.36646.c8 · Cited by 139
CASE-CONTROL STUDIES IN THE EVALUATION OF DRUG-INDUCED ILLNESS
JICK, H., & VESSEY, M. P. (1978) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112502 · Cited by 123
Hormone Replacement Therapy with Estradiol and Risk of Venous Thromboembolism
Abdelnoor, M., Sandset, P. M., & Høibraaten, E. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614363 · Cited by 105
Sitruk-Ware, R. L. (2004) · Drugs & Aging · doi:10.2165/00002512-200421130-00004 · Cited by 102
Poulter, N. R., Chang, C., Farley, T., & Meirik, O. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03132-3 · Cited by 87
The North American Menopause Society (2003) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200310020-00003 · Cited by 85
Plu‐Bureau, G., Lê, M. G., Sitruk-Ware, R. L., Thalabard, J., & MAUVAIS-JARVIS, P. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.291 · Cited by 80
Self-citationImpact of progestagens on activated protein C (APC) resistance among users of oral contraceptives
Alhenc‐Gelas, M., Plu‐Bureau, G., Guillonneau, S., Kirzin, J.-M., Aiach, M., Ochat, N., & Scarabin, P. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00894.x · Cited by 79
Self-citationThe pharmacological profile of a novel norpregnane progestin (trimegestone)
Philibert, D., Bouchoux, F., Degryse, M., Lecaque, D., Petit, F., & Gaillard, M. (1999) · Gynecological Endocrinology · doi:10.3109/09513599909167574 · Cited by 78
van Baal, W. M., EMEIS, J. J., van der Mooren, M. J., van Kessel, H. I., Kenemans, P., & Stehouwer, C. D. A. (2000) · PubMed · Cited by 77
Conard, J., Basdevant, A., Thomas, J.-L., Ochsenbein, E., Denis, C., Guyene, T. T., & Degrelle, H. (1995) · Fertility and Sterility · doi:10.1016/s0015-0282(16)57909-6 · Cited by 74
Self-citationCase-control study of venous thromboembolism risk in users of hormone replacement therapy
Daly, E., Vessey, M. P., Painter, R., & Hawkins, M. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)24041-3 · Cited by 74
Douketis, J. D., Julian, J. A., Kearon, C., Anderson, D. R., Crowther, M. A., Bates, S. M., Barone, M., Piovella, F., Turpie, A. G. G., Middeldorp, S., et al. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01268.x · Cited by 74
Impaired Procoagulant-anticoagulant Balance during Hormone Replacement Therapy?
van Baal, W. M., EMEIS, J. J., van der Mooren, M. J., van Kessel, H. I., Kenemans, P., & Stehouwer, C. D. A. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613752 · Cited by 66
The mechanisms of thrombotic risk induced by hormone replacement therapy
Cano, A., & van Baal, W. M. (2001) · Maturitas · doi:10.1016/s0378-5122(01)00270-5 · Cited by 47
Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism
Simon, T., Canonico, M., Oger, E., Wahl, D. G., Conard, J., Meyer, G., Emmerich, J., Barrellier, M. ‐., Guiraud, A., & Scarabin, P. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01693.x · Cited by 45
Self-citationDouketis, J. D. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.moh.0000161047.53353.a8 · Cited by 24
Post, M. S., Hendriks, D. F., van der Mooren, M. J., van Baal, W. M., Leurs, J., EMEIS, J. J., Kenemans, P., & Stehouwer, C. D. A. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00960.x · Cited by 18
Postmenopausal hormone therapy and cardiovascular disease: An overview of main findings
Canonico, M., Straczek, C., Oger, E., Plu‐Bureau, G., & Scarabin, P. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.04.019 · Cited by 16
Self-citation
Cited by
Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L. C., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., et al. (2022) · International Journal of Transgender Health · doi:10.1080/26895269.2022.2100644 · Cited by 2,698
Hayes, S. N., Kim, E. S. H., Saw, J., Adlam, D., Arslanian-Engoren, C., Economy, K. E., Ganesh, S. K., Gulati, R., Lindsay, M. E., Mieres, J. H., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000564 · Cited by 1,301
Nelson, L. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0808697 · Cited by 1,158
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Metadata
- Authors
- Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., Trillot, N., Barrellier, M.-T., Wahl, D., Emmerich, J., & Scarabin, P.-Y.
- Venue
- Circulation
- Published
- 2007-02-20
- Volume
- 115
- Issue
- 7
- Pages
- 840-845
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2000836832
- Cited by
- 864
- References
- 44
- FWCI
- 40.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.